Analyst Recommendation and Rating

TD Cowen analyst Yaron Werber reiterates a Buy rating on Relay Therapeutics Ltd (NASDAQ: RLAY), highlighting the company’s lead drug candidate zovegalisib (RLY‑2608) as a potential blockbuster franchise with multiple growth avenues.

Clinical Efficacy and Safety Profile

  • In second‑line and later PIK3CA‑mutant metastatic breast cancer, the combination of zovegalisib plus fulvestrant demonstrated a median progression‑free survival (PFS) of 11.1 months, substantially exceeding the approximately 5.5 months observed with AstraZeneca’s Truqap and the 7.4 months with Novartis’s Piqray.
  • Safety data show very low incidences of Grade 3 hyperglycemia, rash, and diarrhea, underscoring a differentiated safety profile.
  • The regimen is currently being evaluated head‑to‑head against standard‑of‑care Truqap plus fulvestrant in the Phase 3 ReDiscover trial.

Market Size Estimates and Commercial Potential

  • Werber’s key opinion leaders project 9‑12 months median PFS for the Phase 3 trial, expecting zovegalisib to capture the majority of the PIK3CA‑mutant market, which represents roughly 35 % of second‑line metastatic breast cancer patients.
  • This segment translates to an estimated U.S. total addressable market (TAM) of $2‑3 billion.
  • Relay is also expanding zovegalisib into first‑line treatment as a triplet with Pfizer’s CDK4 inhibitor atirmociclib. Early data show a 44 % objective response rate (ORR) with favorable safety, and the company plans to launch a Phase 3 trial in early 2027, targeting a larger first‑line TAM of $7‑8 billion.

Additional Indication – Vascular Anomalies

  • In the Phase 2 ReInspire study for vascular anomalies, zovegalisib achieved a 60‑65 % vascular response rate at 12 weeks, markedly higher than the 11‑16 % benchmark for existing therapies.
  • Werber views this as an under‑appreciated opportunity, estimating a U.S. TAM of $6‑8 billion for this indication.

Competitive Landscape

  • The competitive threat from Caelum Biosciences’ gedatolisib is considered diminished following recent data, further strengthening Relay’s positioning.

Disclosure

  • This article was generated with the support of AI and reviewed by an editor. For more information see the terms & conditions.